Abstract
Background
Botulinum toxin-A (BTX-A) is recent technique to treat gummy smile.
Objectives
This randomized controlled preliminary clinical trial evaluated BTX-A on excessive gingiva display (EGD) reduction, muscle activity, and patient satisfaction at 2, 8, 12, 16, 21, and 25 weeks.
Methods
Group 1(G1): 4 points of BTX-A application (2U/point) for relaxation of the levatorlabii superioris alaeque nasi (LLSAN) and levatorlabiisuperioris (LLS) muscles; Group 2(G2): Two points of BTX-A (2U/point) for relaxation of the LLSAN muscle.
Results
A high dropout of patients during some follow-up sessions occurred. So, considering this data limitation, the results found were considered a preliminary outcome. In 2 weeks, there was a significant difference between baseline regarding the reduction of EGD in G1 and G2, reduction in muscle activity in G1, and increased satisfaction in G1 and G2. In 2 weeks, there was no difference between both groups. Statistical EGD reduction was maintained until 16 weeks for G2 and 25 weeks in G1. After 14 days there was a gradual recovery of muscle activity in both groups until baseline values recovery within 25 weeks. Patients' satisfaction with treatment lasted 21 weeks in G1 and 16 weeks in G2.
Conclusions
Increasing BTX-A injection points resulted in a prolonged effect regarding EGD reduction and patient satisfaction but did not increase the intensity of the outcome. However, due to the high dropout of patients, this is a suggested preliminary conclusion based on available data and more additional studies are necessary to testify the results described.